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ABSTRACT
Introduction: National guidelines do not suppor t r outine empir ic vancomycin use in the initial
management of febrile neutropenia (FN) and only recommend it in patients with specific clinical
indications. This bi-phasic quality improvement project aimed to evaluate current vancomycin use in
FN and improve compliance with a guideline-driven algorithm (GDA) to ensure appropriate prescribing
and therapy duration in a community hospital.
Methods: Phase I was a retrospective review of charts of adults receiving empiric vancomycin therapy
for FN at a community hospital. Phase II was a prospective review of charts of patients with FN, who
received pharmacist-led interventions, to improve de-escalation of vancomycin as warranted.
Results: A total of 48 and 32 patients were included in phase I and phase II, respectively. While
initiation of vancomycin therapy according to guideline-recommended clinical indications was
comparable among phases, appropriate de-escalation of vancomycin increased from 23% in phase I to
78% in phase II. Overall compliance with the GDA increased from 15% in phase I to 38% in phase II.
Average duration of therapy in phase I was 4.77 days versus 2.69 days in phase II and there were less
patients who continued vancomycin beyond 48 hours in phase II. The pharmacy intervention rate was
56% (18 of 32) and the health-care practitioner acceptance rate was 100%.
Discussion: Pharmacist interventions had an impact in increasing compliance with national guideline
recommendations and decreasing the duration of empiric vancomycin therapy in patients with FN.
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INTRODUCTION
Febrile neutropenia (FN) is the cause of an
astounding annual number of cancer-related
hospitalizations – approximately 60,000 per year
(Tai et al., 2017). Febrile neutropenia is a complication of chemotherapy resulting in a temperature
of 100.4⁰F or greater accompanied by an absolute
neutrophil count (ANC) below 500 cells/mm3 or
an ANC below 1000 cells/mm3 and expected to
decrease below 500 cells/mm3 within 48 hours
(Patel & West, 2017). Febrile neutropenia occurs
in approximately 50% of solid tumors and over
80% of hematologic malignancies. It can occur
any time during the course of illness, from as
early as the time of diagnosis to end-stage
disease. Patients with FN are not only at a higher

risk of infection, but are more likely to experience
more severe infection (Patel & West, 2017).
Therefore, timely administration of empiric
antibiotics in this subset of patients is crucial for
reducing morbidity and mortality. However,
prolonged empiric antimicrobial treatment can
lead to antimicrobial resistance (e.g. dissemination of vancomycin-resistant organisms) and
organ toxicity (e.g. acute kidney injury) (Freifeld
et al., 2011; Paul et al., 2005). Previous studies
have failed to show a true clinical advantage with
the addition of vancomycin to empiric therapy
(Paul et al., 2005). The European Organization
for Research and Treatment of Cancer (EORTC,
1991) conducted a randomized clinical trial
consisting of 747 patients (“Vancomycin added to
empirical combination antibiotic therapy for fever
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in granulocytopenic cancer patients”). The
patients were randomized to receive ceftazidime
and amikacin with or without vancomycin. The
results showed no significant difference in
duration of fever or improvement in survival.
However, antibiotic-associated nephrotoxicity
was more frequent in the vancomycin arm.
According to the National Comprehensive Cancer
Network (NCCN, 2021) and Infectious Diseases
Society of America (IDSA) guidelines (Freifeld et
al., 2011), routine addition of vancomycin to
empiric antimicrobial regimens to treat FN is not
recommended. Vancomycin is only recommended
in patients with specific clinical indications such
as suspected catheter-related infection, hemodynamic instability, skin or soft-tissue infection,
colonization with penicillin (PCN)/cephalosporinresistant pneumococci or methicillin-resistant
Staphylococcus aureus (MRSA), preliminary
gram positive blood cultures, pneumonia, and
severe and refractory mucositis (summarized in
Table 1). The guidelines also acknowledge the
use of vancomycin in the setting of a severe beta
lactam allergy (Freifeld et al., 2011; NCCN,
2021). The purpose of this project was to evaluate
current use of vancomycin for FN and improve
compliance with a guideline-driven algorithm
(GDA) to ensure appropriate prescribing and
therapy duration within a local South Florida
community hospital.
METHODS
This was a biphasic, IRB-reviewed quality
improvement project evaluating adult patients
receiving empiric vancomycin therapy for FN.
This single-center project was conducted at a
not-for-profit community hospital with over 900
beds that serves a significant amount of oncology
patients as it is associated with a large neighboring cancer center. The community hospital has 84
inpatient oncology beds between two dedicated
floors. Phase I of this project was a retrospective
evaluation of therapy based on National Oncology guidelines from January 2019 to December
2019, while phase II was a prospective evaluation
of therapy based on guidelines from January 2021
to March 2021. An algorithm based on national
guidelines was created to guide pharmacists’
de-escalation interventions in phase II. The
algorithm also provided a systematic method to
assess adherence to national guideline recommendations and incorporated recommendations for
appropriate initiation and de-escalation of vanco55
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mycin empiric therapy. The GDA is summarized
in Figure 1.
Patients were identified using vancomycin
dispense reports generated through the electronic
medical record reporting software. Patients were
included if they were 18 years and older with a
vancomycin order for the selected indication of
“neutropenic fever,” “sepsis of unknown origin,”
or “other.” Patients with one-time orders of
vancomycin and patients who lacked a documented diagnosis or did not meet the clinical definition
of FN were excluded. Oncology pharmacists were
provided with an educational presentation to help
identify patients meeting inclusion criteria in
phase II for timely intervention. Data collection
variables included patient demographics, indication, pertinent labs and cultures, therapy duration
and compliance with the GDA. In phase II,
pharmacists implemented an algorithm to recommend de-escalation or discontinuation of vancomycin as warranted. Data were collected, stored,
and analyzed using Microsoft Excel. Descriptive
statistics were used to report results.
RESULTS
Forty-eight patients were included in phase I,
and 32 patients were included in phase II. Subject
characteristics (summarized in Table 2) were
similar across phases with the exception of age,
bone marrow transplant (BMT) status, positive
cultures, and acute kidney injury. Phase II had a
higher average patient age and higher percentage
of BMT patients, while phase I had a higher
percentage of patients with positive blood
cultures and acute kidney injury. The percentage
of patients initiated on vancomycin empiric therapy in the presence of guideline-recommended
clinical indications was 42% in phase I versus
41% in phase II. The rate of appropriate
de-escalation increased from 23% in phase I to
78% in phase II. The overall compliance with the
GDA, which is defined as both appropriate initiation and de-escalation of empiric vancomycin,
increased from 15% in phase I to 38% in phase II
(See Table 3). The average duration of therapy
decreased from 4.77 days (range: 1 to 16 days) in
phase I, to 2.69 days (range: 1 to 9 days) in phase
II. The number of patients who continued on
empiric vancomycin beyond 48 hours decreased
from phase I to phase II (See Figure 2). In the
prospective interventional phase, 18 pharmacyinitiated interventions were made at an intervention rate of 56%. All interventions were accepted
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by the physician or advanced practitioner for an
acceptance rate of 100%. The pharmacy-initiated
interventions included discontinuation of vancomycin (94.4%) and vancomycin dose optimization (5.6%).
DISCUSSION
The results of this project show that pharmacist intervention resulted in a higher percent
compliance with national guideline recommendations and a shorter duration of empiric vancomycin therapy in FN. The largest impact related to
pharmacist intervention was de-escalation of
empiric vancomycin therapy. The comparability
of the total percentage of patients initiated on
vancomycin with guideline-recommended clinical
indications among phases highlights the valuable
role of the pharmacist in de-escalation of empiric
antimicrobial therapy in the absence of positive
blood cultures. However, the project had significant limitations. Some limitations of this project
included the small sample size and short duration,
being that the prospective intervention was only
three months in duration and occurred during
weekdays and business hours. Additionally,
compliance with the GDA was reported as an “all
-or-nothing” approach, meaning that vancomycin
had to be both initiated in a patient with guideline
-recommended clinical indications as well as
de-escalated appropriately in order to be considered compliant. There was little opportunity to
impact initiation in this particular project, and this
should be evaluated in the future. Lastly, the
expansion of oncology services allowed for
disparity in patient volume between phases due to
the ability to accommodate more oncology
patients in phase II. Currently throughout the
health care system, the sepsis protocol drives the
use of vancomycin in febrile neutropenia. Therefore, a future direction for this project is to
streamline the criteria for vancomycin use in FN
to specifically include the clinical indications set
forth by NCCN/IDSA guidelines and separate it
from the criteria for vancomycin use in sepsis.
Moreover, a significant number of patients were
excluded from the project due to being one-time
orders. Therefore, it may be beneficial to conduct
a medication-use evaluation of one-time orders
for vancomycin for FN to evaluate whether there
is an opportunity to optimize one-time ordering of
vancomycin in FN.

CONCLUSION
Pharmacist interventions had an impact in
increasing compliance with national guideline
recommendations and decreasing the duration of
empiric vancomycin therapy in patients with FN.
Therefore, clinical pharmacists should routinely
evaluate empiric vancomycin orders in patients
with FN for the presence of guidelinerecommended clinical indications and follow up
to ensure optimal duration of therapy.
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Table 1
Summary of Guideline Recommendations for Empiric Addition of Vancomycin in Febrile Neutropenia
Clinical Indication

IDSA

NCCN

Suspected catheter-related infection





Hemodynamic/clinical instability





Known colonization with Penicillin/Cephalosporin-resistant
pneumococci or MRSA





Skin or soft tissue infection





Gram positive blood cultures





Pneumonia documented radiographically



Severe mucositis (if fluoroquinolone prophylaxis AND
ceftazidime use empirically)



Note. This table summarizes the guideline-recommended clinical indications for empiric addition of
vancomycin in febrile neutropenia.

IDSA = Infectious Diseases of America, NCCN = National Comprehensive Cancer Network
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Table 2
Subject Characteristics
Characteristic

Phase I

Phase II

(n=48)
67 (SD 15.9)

(n=32)
60 (SD 13.6)

Median ANC, cells/mm3

0.26 (IQR 0.7)

0.29 (IQR 0.6)

Average Tmax, ⁰C

38.6 (SD 0.8)

38.6 (SD 0.8)

BMT, n (%)

3 (6.3%)

13 (40.6%)

PCN allergy, n (%)

5 (10.4%)

5 (15.6%)

1.1 (IQR 0.7)

0.97 (IQR 0.5)

Acute kidney injury, n (%)

9 (18.8%)

2 (6.3%)

Positive blood culture, n (%)

12 (25%)

5 (15.6%)

Average age, years

Median baseline SCr, mg/dL

MRSA/MRSE

2 (4.17%)

1 (3.13%)

Selected indication, n (%)

Febrile neutropenia

32(66.7%)

24 (75%)

Sepsis, no clear source

10 (20.8%)

5 (15.6%)

Other

6 (12.5%)

3 (9.4%)

Home

33 (68.7%)

30 (93.7%)

Expired

13 (27.1%)

2 (6.3%)

2 (4.2%)

–

Disposition n (%)

Nursing Facility

Note. This table summarizes the subject characteristics in phase I vs. phase II.

SD = Standard deviation, IQR = Interquartile range
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Table 3
Percent Compliance with GDA
Phase I

Phase II

(n=48)

(n=32)

Initiated with Clinical Indications, n (%)

20 (42%)

13 (41%)

De-escalated within 48 Hours, n (%)

11 (23%)

25 (78%)

Overall compliance with GDA, n (%)

7 (15%)

12 (38%)

Characteristic

Note. This table summarizes the percent compliance with the guideline-driven algorithm as it relates to
initiation, de-escalation, and compliance to the algorithm as a whole.

Figure 1
Summary of Guideline-Driven Algorithm
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Figure 2
Duration of Therapy
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